Evidence map›Paper›PMID 41423517›Full record

ArticleScientific reports2025

Cellular heterogeneity and therapeutic response profiling of human IDH + glioma stem cell cultures.

Nyasha Chambwe, Scott R Kennedy, Brendan F Kohrn, Pavlo Lazarchuk, Mario Leutert, Guangrong Qin, Bahar Tercan, Monica Sanchez-Contreras, Weiliang Tang, Jerome J Graber and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Nyasha Chambwe *Institute for Systems Biology, Seattle, WA, USA.
Scott R Kennedy *Departments of Laboratory Medicine and Pathology, Genome Sciences, Bioengineering, and Neurology and Neurosurgery, University of Washington, Seattle, WA, USA.
Brendan F Kohrn *Departments of Laboratory Medicine and Pathology, Genome Sciences, Bioengineering, and Neurology and Neurosurgery, University of Washington, Seattle, WA, USA.
Pavlo Lazarchuk *Departments of Laboratory Medicine and Pathology, Genome Sciences, Bioengineering, and Neurology and Neurosurgery, University of Washington, Seattle, WA, USA.
Mario Leutert *Departments of Laboratory Medicine and Pathology, Genome Sciences, Bioengineering, and Neurology and Neurosurgery, University of Washington, Seattle, WA, USA.
Guangrong Qin *Institute for Systems Biology, Seattle, WA, USA.
Bahar Tercan *Institute for Systems Biology, Seattle, WA, USA.
Monica Sanchez-ContrerasDepartments of Laboratory Medicine and Pathology, Genome Sciences, Bioengineering, and Neurology and Neurosurgery, University of Washington, Seattle, WA, USA.
Weiliang TangDepartments of Laboratory Medicine and Pathology, Genome Sciences, Bioengineering, and Neurology and Neurosurgery, University of Washington, Seattle, WA, USA.
Jerome J GraberDepartments of Laboratory Medicine and Pathology, Genome Sciences, Bioengineering, and Neurology and Neurosurgery, University of Washington, Seattle, WA, USA.
Patrick J PaddisonFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Judit VillénDepartments of Laboratory Medicine and Pathology, Genome Sciences, Bioengineering, and Neurology and Neurosurgery, University of Washington, Seattle, WA, USA.
Ilya ShmulevichInstitute for Systems Biology, Seattle, WA, USA.
Raymond J MonnatDepartments of Laboratory Medicine and Pathology, Genome Sciences, Bioengineering, and Neurology and Neurosurgery, University of Washington, Seattle, WA, USA. monnat@uw.edu.

Funding

The role of phosphorylation in the cellular organization of the proteomeR35GM152061 · NIGMS · UNIVERSITY OF WASHINGTON · PI Judit Villen · 2024 to 2026
$1.3M
Understanding the regulation of mtDNA heteroplasmy and integrityR35GM153370 · NIGMS · UNIVERSITY OF WASHINGTON · PI Scott Robert Kennedy · 2024 to 2026
$1.2M
NIGMS NIH HHS R35 GM152061NIGMS NIH HHS R35 GM153370
6 · The paper itself

Abstract

Glioblastoma stem cell (GSC) cultures are initiated from glioblastoma (GBM) surgical resection tissue. When grown appropriately they can capture and propagate key GBM molecular and cellular features. We have characterized cellular, genomic and proteomic features of four isocitrate dehydrogenase (IDH)-expressing (IDH +) GSC cultures as cellular models for ~ 90% of adult GBMs. We demonstrate that GSC cultures can be continuously propagated in defined, serum-free media and 5% oxygen without specialized growth substrates; have culture-specific genomic and mtDNA variants together with gene/protein expression profiles; and display reproducible dose-survival curves for the GBM standard-of-care therapies ionizing radiation (IR) and temozolomide (TMZ). In order to better define GSC culture cellular heterogeneity and dynamics, we used lentiviral DNA barcoding, mtDNA variants and single cell gene expression profiling over 40 days after IR treatment. GSC cultures are versatile in their ability to support many in vitro protocols including high throughput screens as well as xenograft, organoid and other disease modeling protocols. They provide a simple cellular disease model for better understanding GBM biology, and for identifying new, potentially more effective GBM therapies and treatment regimens.

Indexed as

Brain NeoplasmsGlioblastomaGliomaIsocitrate DehydrogenaseNeoplastic Stem CellsGene Expression ProfilingHumansTemozolomideTumor Cells, CulturedIsocitrate DehydrogenaseTemozolomideCellular disease modelCellular heterogeneityGlioblastomaGlioma stem cellProteogenomic subtypingRadiation response

Identifiers

PMID41423517
PMCPMC12830798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.